Table 2.

Age-and sex-adjusted rates of hypertension, elevated levels of low lipoprotein cholesterol, type 2 diabetes, treatment and control among BMI categories

	% of Participants (95% CI)
	BMI 18.5-<25	BMI 25-<30	BMI ≥30	p-value*
	N=2458	N=2596	N=1747
Hypertension
Prevalence	11.5 (10.2–12.9)	22.8 (21.0–24.8)	37.6 (34.5–40.7)	<0.001
Treatment	58.7 (49.8–67.1)	59.0 (52.8–65.0)	62.3 (56.1–68.2)	0.002
Control	36.7 (30.3–43.5)	37.3 (32.7–41.9)	39.4 (34.9–44.0)	0.48
Elevated LDL-C levels
Prevalence	12.7 (11.3–14.2)	28.2 (26.2–30.4)	35.1 (32.2–38.2)	<0.001
Treatment	34.2 (28.2–40.6)	36.4 (32.3–40.6)	39.5 (34.9–44.4)	0.02
Control	26.7 (21.5–32.4)	26.0 (22.6–29.7)	29.2 (25.3–33.4)	0.11
Diabetes
Prevalence	1.4 (0.9–1.9)	4.1 (3.4–5.0)	11.9 (10.3–13.6)	<0.001
Treatment	69.2 (38.6–90.9)	50.0 (35.2–64.8)	55.0 (44.7–65.0)	0.54
Hb A1c <7.0% †	50.0 (18.7–81.3)	58.8 (40.7–75.4)	47.7 (35.3–59.4)	0.26
FPG <126 mg/dL	30.4 (13.2–52.9)	20.7 (12.8–30.7)	15.7 (10.8–21.7)	0.02

Abbreviations: CI, confidence interval; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; Hb A1c, Hemoglobin A_1c level; FPG, fasting plasma glucose

SI conversion factor: To convert fasting plasma glucose to mmol/L, multiply mg/dL values by 0.0555

^*Global GEE p-value

^†Data only available for Offspring cohort